从战略布局到清算退场，锐康迪折戟中国罕见病市场

Core Viewpoint - Recordati's subsidiary, Ricordi, has officially entered liquidation and will cease all operations in the Chinese rare disease market, marking a significant exit from this sector [1][2]. Group 1: Company Operations and Products - Ricordi had three approved rare disease drugs in China: Carbamoyl Glutamic Acid Tablets (Kaba Guo®), Phosphate Ozoniside Tablets (Shi Rui Sa®), and Injection of Hydroxy-Naphthyl Acetic Acid Parepitide Microspheres (Sai Ni Fen®) [1][2]. - The company initiated its operations in China in 2021, focusing solely on the rare disease segment, which was experiencing a surge in policy support [2]. - The commercial launch timeline for Ricordi's products includes Carbamoyl Glutamic Acid Tablets approved in June 2023 and launched in November 2023, with Phosphate Ozoniside Tablets and Injection of Hydroxy-Naphthyl Acetic Acid Parepitide Microspheres expected to follow in 2024 and 2025 respectively [3]. Group 2: Market Challenges and Patient Impact - The exit of Ricordi from the Chinese market raises concerns about treatment continuity for rare disease patients, who already face challenges such as low awareness, difficult diagnoses, and insufficient insurance coverage [1][5]. - The company had previously attempted to improve drug accessibility through patient assistance programs and inclusion in local health insurance schemes [4]. - The challenges faced by Ricordi highlight broader issues in the commercialization of rare disease drugs in China, including high R&D costs and the need for a sustainable support system for patients [1][6]. Group 3: Industry Context and Future Outlook - The exit of Ricordi reflects a broader trend among multinational pharmaceutical companies reassessing their strategies in the Chinese market, particularly in the rare disease sector [7][8]. - Despite advancements in the rare disease drug coverage system, significant gaps remain, impacting the commercial viability of these drugs [8]. - Future discussions will focus on whether Ricordi's approved products can return to the Chinese market through policy channels or be taken over by other companies to continue supplying these essential treatments [6].